Acurx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Acurx Pharmaceuticals, Inc. (ACXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.25%, a 0.70% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.28%, a 11.17% increase year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.85%, a 126.47% increase year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.70%.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.25%, a 0.70% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.28%, a 11.17% increase from fiscal 2023.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.85%, a 91.54% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.01%, a 84.40% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.00% 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | 4.25% 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 4.25% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 4.25% 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 4.25% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 4.28% 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 4.28% 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 4.28% 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | 4.28% 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | 3.85% 10-K · filed 2025-03-17 | |||
| 2023-09-30 | 3.85% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 3.85% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 3.85% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 2.01% 10-K · filed 2024-03-15 | |||
| 2022-09-30 | 2.01% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 2.01% 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | 1.70% 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 1.09% 10-K · filed 2022-03-16 | |||
| 2021-09-30 | 1.09% 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | 1.08% 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |